MICU2 Antibody

What is MICU2 and why is it important in cellular function?

MICU2 functions as a calcium sensor of the mitochondrial calcium uniporter (MCU) channel, sensing calcium levels via its EF-hand domains. MICU2 forms a disulfide-linked heterodimer with MICU1 that regulates MCU activity in a calcium-dependent manner. At low calcium levels, the MICU1-MICU2 complex occludes the pore of the MCU channel, preventing mitochondrial calcium uptake. When calcium levels increase, calcium binding to the heterodimer induces conformational changes that allow calcium permeation through the channel . This gatekeeping function is essential for maintaining mitochondrial calcium homeostasis, which is critical for energy production, cell survival, and various signaling pathways.

What applications are MICU2 antibodies validated for?

MICU2 antibodies have been validated for multiple research applications:

Most commercial MICU2 antibodies are raised against recombinant fragments of human MICU2 protein (typically within amino acids 50-250) and are available as rabbit polyclonal antibodies . When selecting an antibody, researchers should verify the specific epitope region and species reactivity based on their experimental needs.

How is MICU2 protein detected in mitochondrial preparations?

Detection of MICU2 in mitochondrial preparations typically involves:

• Isolation of mitochondria using differential centrifugation or commercial isolation kits

• Lysis of mitochondria in buffers containing detergents (e.g., 0.2% DDM with protease inhibitors)

• Separation of proteins via SDS-PAGE (usually 12% gels for optimal resolution)

• Transfer to PVDF or nitrocellulose membranes

• Blocking with appropriate blocking buffer (typically 5% BSA)

• Incubation with anti-MICU2 antibody (recommended dilutions range from 1:500 to 1:2000)

• Detection with secondary antibodies and visualization systems

In non-reducing Western blots, the MICU1-MICU2 heterodimer appears as a single band at approximately 95 kDa that reacts with both MICU1 and MICU2 antibodies . Under reducing conditions, MICU2 is typically observed at its monomeric molecular weight of 45-50 kDa .

What are the optimal conditions for MICU2 antibody use in Western blotting?

Optimized Western blotting conditions for MICU2 detection include:

For studying the MICU1-MICU2 heterodimer, researchers should consider using non-reducing conditions to preserve the disulfide linkage between the proteins . For detection of monomeric MICU2, standard reducing conditions with DTT or β-mercaptoethanol should be used.

How can MICU2 antibodies be used in co-immunoprecipitation studies?

For co-immunoprecipitation of MICU2 with interaction partners:

• Lyse cells or isolated mitochondria in buffer containing mild detergents (0.2% DDM recommended) with protease inhibitors and EDTA

• Clear lysates by centrifugation (16,000g for 10 minutes at 4°C)

• Pre-clear lysate with control beads to reduce non-specific binding

• Incubate cleared lysate with anti-MICU2 antibody (2-5 μg) or anti-tag antibody for tagged constructs

• Add protein A/G beads and incubate for 2-4 hours at 4°C with gentle rocking

• Wash immunoprecipitates 3-5 times with lysis buffer

• Elute proteins by boiling in sample buffer

• Analyze by SDS-PAGE and Western blotting for MICU2 and potential interaction partners

This approach has been successfully used to demonstrate MICU1-MICU2 interactions and to identify novel binding partners . When studying calcium-dependent interactions, researchers should control calcium levels by including either calcium or chelators (EGTA/EDTA) in the buffers.

What controls should be included in MICU2 knockdown/knockout validation experiments?

Proper validation of MICU2 knockdown or knockout requires multiple controls:

When validating MICU2 knockdown, researchers should assess not only MICU2 levels but also MICU1 levels, as MICU2 stability depends on MICU1 expression . Importantly, MICU1 expression is not dependent on MICU2, which allows for specific assessment of MICU2 function .

How do MICU1 and MICU2 antibodies help elucidate the stoichiometry and structure of the MCU complex?

Advanced structural studies of the MCU complex have employed MICU1 and MICU2 antibodies in combination with biochemical techniques:

These approaches have been instrumental in establishing that MICU1 and MICU2 form a heterodimer that regulates MCU function through a complex conformational mechanism dependent on calcium levels .

What are the best approaches for studying MICU2 in primary tissues versus cell lines?

Detecting and studying MICU2 in primary tissues requires different approaches compared to cell lines:

For primary cardiac tissue samples, researchers have successfully employed immunoblotting of isolated mitochondria to detect MICU2 and other MCU components . For brain and other tissues with high heterogeneity, immunohistochemistry with MICU2 antibodies has been valuable for determining cell type-specific expression patterns .

In mouse models, both conventional knockout and tissue-specific knockout approaches for MICU2 have been developed, providing valuable controls for antibody validation in primary tissues .

How can calcium-dependent conformational changes in MICU2 be studied using antibody-based approaches?

Calcium-dependent conformational changes in MICU2 can be investigated using several antibody-based techniques:

• Limited proteolysis combined with epitope-specific antibodies: Treatment of purified MICU2 or mitochondrial preparations with proteases in the presence or absence of calcium, followed by detection with antibodies recognizing different epitopes, can reveal conformational changes that alter epitope accessibility .

• Proximity ligation assays (PLA): Using antibodies against MICU1 and MICU2 in fixed cells or tissues, PLA can detect changes in the proximity or orientation of these proteins under different calcium conditions .

• Förster resonance energy transfer (FRET): Antibody fragments labeled with fluorophores can be used to monitor distance changes between domains of MICU1 and MICU2 in response to calcium binding .

• Hydrogen-deuterium exchange mass spectrometry (HDX-MS): Combined with antibody pulldown, this technique can identify regions of MICU2 that undergo structural changes upon calcium binding .

These approaches have revealed that calcium binding to the EF-hand domains of MICU1 and MICU2 induces significant conformational changes that alter the interaction between the MICU1-MICU2 heterodimer and the MCU channel .

How can MICU2 antibodies be used to investigate its role in cardiovascular diseases?

MICU2 antibodies have been instrumental in investigating cardiovascular pathologies:

• Protein expression analysis: Western blotting with MICU2 antibodies has revealed that MICU2 expression is elevated in cardiovascular pathologies in both humans and mice .

• Immunohistochemistry: MICU2 antibodies have been used to visualize the distribution of MICU2 in cardiac tissues, showing its presence in cardiomyocytes and vascular cells .

• Single-cell analysis: Combined with cell sorting and RNA-seq, MICU2 immunostaining has helped identify cell type-specific responses in aortic tissue, revealing that MICU2 is expressed in endothelial, smooth muscle, and fibroblast cells within the aorta .

• Animal models: MICU2 antibodies have been used to validate knockout models that demonstrated a protective role for MICU2 against hypertension-induced aortic aneurysms. These studies showed that MICU2-deficient mice develop abdominal aortic aneurysms with spontaneous rupture when exposed to angiotensin II .

• Mitochondrial calcium measurement: In combination with calcium indicators, MICU2 antibodies have helped correlate MICU2 expression with alterations in mitochondrial calcium handling in cardiomyocytes .

These applications have established that MICU2 plays a critical role in maintaining cardiovascular homeostasis by regulating mitochondrial calcium uptake in cardiac and vascular cells.

What methods can be used to investigate MICU2's role in cancer using antibody-based approaches?

Several antibody-based approaches have been employed to study MICU2's role in cancer:

• Tissue microarray analysis: MICU2 antibodies have been used for immunohistochemical staining of cancer tissue microarrays to correlate MICU2 expression with clinical outcomes .

• Western blot analysis of patient samples: MICU2 protein levels in tumor versus normal tissues have been assessed using Western blotting, revealing that MICU2 is often upregulated in colorectal cancer (CRC) and correlates with cancer stage .

• Functional analysis in cancer cell lines: MICU2 knockdown followed by antibody validation has been used to study the effects on mitochondrial calcium uptake, cell proliferation, and migration in cancer cells .

• Protein complex composition analysis: Blue native PAGE combined with Western blotting has revealed alterations in the MCU complex composition in cancer cells with modified MICU2 expression .

Research has shown that MICU2 upregulation enhances tumor aggressiveness in colorectal cancer, with MICU2 expression and the MICU2/MICU1 ratio tightly correlated to CRC aggressiveness and stage. MICU2 regulates cancer cell proliferation and migration both in vitro and in vivo .

How can MICU2 antibodies be used to investigate beta cell dysfunction in metabolic disorders?

MICU2 antibodies have been utilized to study beta cell function in several ways:

• Expression analysis in pancreatic islets: Western blotting and immunohistochemistry with MICU2 antibodies have been used to quantify MICU2 levels in pancreatic beta cells under normal and pathological conditions .

• Subcellular localization: Immunofluorescence with MICU2 antibodies has helped determine the precise localization of MICU2 in beta cell mitochondria and its potential colocalization with other calcium handling proteins .

• Knockout validation: MICU2 antibodies have been essential for confirming the effectiveness of MICU2 knockout in beta cell-specific models, such as in the INS-1 832/13 and EndoC-βH1 cell lines .

• Functional correlation: Combined with insulin secretion assays, MICU2 antibody staining has helped correlate MICU2 expression levels with beta cell function .

Research has demonstrated that MICU2 plays a critical role in beta cell mitochondrial calcium uptake. Beta cell mitochondria sequester calcium from the submembrane compartment, preventing excessive activation of plasma membrane K(ATP) channels. MICU2 knockdown impairs glucose-stimulated insulin secretion, indicating its importance in normal beta cell function .

How can researchers distinguish between MICU1 homodimers and MICU1-MICU2 heterodimers using antibody-based techniques?

Distinguishing between MICU1 homodimers and MICU1-MICU2 heterodimers requires specialized approaches:

• Non-reducing SDS-PAGE: Under non-reducing conditions, MICU1-MICU2 heterodimers appear as a single band at ~95 kDa that reacts with both MICU1 and MICU2 antibodies. In contrast, MICU1 homodimers (present in MICU2 knockout cells) appear at ~100 kDa and react only with MICU1 antibodies .

• Sequential immunoprecipitation: First, immunoprecipitate with anti-MICU1 antibodies, then perform a second immunoprecipitation on the eluate using anti-MICU2 antibodies. This approach allows separation of heterodimers from homodimers .

• Blue native PAGE: This technique separates native protein complexes based on size and can distinguish between MICU1 homodimers and MICU1-MICU2 heterodimers when followed by Western blotting with specific antibodies .

• Proximity ligation assay: This technique can specifically detect heterodimers in situ by using antibodies against MICU1 and MICU2 simultaneously .

What are the challenges in detecting calcium-bound versus calcium-free forms of MICU2?

Detecting the calcium-binding state of MICU2 presents several challenges:

Research has shown that calcium binding to MICU1 and MICU2 induces conformational changes that affect the interaction between the heterodimer and the MCU channel . The calcium-free and calcium-bound states have different functional properties in regulating mitochondrial calcium uptake, making the ability to distinguish these states important for understanding MICU2 function .

How should researchers approach epitope mapping for MICU2 antibodies in structural studies?

Epitope mapping for MICU2 antibodies requires systematic approaches:

• Peptide arrays: Synthesize overlapping peptides spanning the MICU2 sequence and test antibody binding to identify linear epitopes.

• Truncation mutants: Generate a series of N- and C-terminal truncations of MICU2 to narrow down the antibody binding region.

• Alanine scanning: Systematically substitute alanine for residues in the suspected epitope region and test for loss of antibody binding.

• Cross-species comparison: Compare antibody reactivity against MICU2 from different species to identify conserved epitopes.

• Competition assays: Use purified domains or peptides to compete for antibody binding in immunoassays.

• X-ray crystallography or cryo-EM: Determine the structure of antibody-antigen complexes for precise epitope mapping.

Understanding the exact epitope is particularly important for structural studies of MICU2, as the protein undergoes significant conformational changes upon calcium binding . Antibodies binding to regions involved in these conformational changes may affect protein function or provide valuable tools for detecting specific conformational states.